Citizens Jmp Reiterates “Market Outperform” Rating for Bicara Therapeutics (NASDAQ:BCAX)

Bicara Therapeutics (NASDAQ:BCAX)‘s stock had its “market outperform” rating reissued by investment analysts at Citizens Jmp in a note issued to investors on Tuesday,Benzinga reports. They presently have a $31.00 target price on the stock. Citizens Jmp’s price target would suggest a potential upside of 51.22% from the stock’s previous close.

A number of other research analysts have also recently commented on the company. Bank of America started coverage on Bicara Therapeutics in a research report on Wednesday, March 25th. They set a “buy” rating and a $35.00 price target on the stock. Mizuho raised Bicara Therapeutics to a “hold” rating in a report on Thursday, December 18th. Wedbush restated an “outperform” rating and issued a $30.00 price objective on shares of Bicara Therapeutics in a research note on Tuesday, January 13th. BTIG Research reaffirmed a “buy” rating on shares of Bicara Therapeutics in a report on Thursday, January 15th. Finally, HC Wainwright increased their target price on shares of Bicara Therapeutics from $40.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday. Eight investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Bicara Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $28.00.

Bicara Therapeutics Trading Up 3.1%

NASDAQ:BCAX opened at $20.50 on Tuesday. Bicara Therapeutics has a 12 month low of $7.80 and a 12 month high of $21.05. The firm’s 50 day moving average is $17.28 and its 200 day moving average is $16.69. The stock has a market capitalization of $1.34 billion, a PE ratio of -8.10 and a beta of -1.24.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings data on Monday, March 30th. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.04. Research analysts predict that Bicara Therapeutics will post -2.59 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Ivan Hyep sold 9,200 shares of the stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $18.52, for a total transaction of $170,384.00. Following the sale, the chief financial officer owned 145,355 shares of the company’s stock, valued at approximately $2,691,974.60. This represents a 5.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Ryan Cohlhepp sold 12,500 shares of the firm’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $19.66, for a total value of $245,750.00. Following the completion of the transaction, the chief operating officer owned 200,641 shares of the company’s stock, valued at approximately $3,944,602.06. This represents a 5.86% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 137,969 shares of company stock worth $2,586,198. Insiders own 15.50% of the company’s stock.

Institutional Investors Weigh In On Bicara Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Bicara Therapeutics by 385.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock worth $97,000 after buying an additional 4,585 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its stake in Bicara Therapeutics by 596.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock valued at $54,472,000 after acquiring an additional 2,771,868 shares in the last quarter. Invesco Ltd. grew its stake in Bicara Therapeutics by 20.6% during the fourth quarter. Invesco Ltd. now owns 21,006 shares of the company’s stock valued at $354,000 after acquiring an additional 3,595 shares in the last quarter. VARCOV Co. bought a new stake in Bicara Therapeutics during the 4th quarter worth approximately $263,000. Finally, Virtus Investment Advisers LLC increased its holdings in Bicara Therapeutics by 46.4% during the 4th quarter. Virtus Investment Advisers LLC now owns 14,395 shares of the company’s stock worth $242,000 after acquiring an additional 4,560 shares during the period.

Bicara Therapeutics News Summary

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Wall Street analyst consensus implies a large upside (~54.9%) to BCAX based on average price targets and improving earnings-estimate revisions, a factor traders cite as justification for buying interest. Wall Street Analysts Believe Bicara Therapeutics Inc. (BCAX) Could Rally 54.85%: Here’s is How to Trade
• Positive Sentiment: Clinical progress: Seeking Alpha reiterates a Buy rating as BCAX advances its pivotal phase 3 FORTIFI-HN01 study; strong phase 1/1b signals (12‑month OS 61%, ORR 54% with ficerafusp alfa + KEYTRUDA) support the program. Key upcoming catalysts: phase‑3 interim readout mid‑2027 and long‑term phase 1b follow‑up at ASCO 2026. Near‑full enrollment expected by year‑end. Bicara: Maintaining ‘Buy’ Rating On Ficerafusp Alfa Phase 3 Advancement
• Positive Sentiment: Q4 / cash position: Earnings call highlights show a stronger cash position and a slight beat on Q4 EPS vs. estimates, which reduces near‑term dilution risk and supports runway for clinical execution. Bicara Therapeutics Inc (BCAX) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Full Q4 earnings call transcript is available for investors digging into management comments on timelines and cash burn; useful for detailed diligence but not a single price driver by itself. Q4 2025 earnings call transcript
• Negative Sentiment: Mixed analyst views: Goldman Sachs raised its PT to $16 (neutral) and Wells Fargo to $16 (equal‑weight)—both targets sit well below the current market price, implying downside from their perspective. These conservative calls can cap near‑term upside and add volatility. Benzinga coverage of analyst moves
• Positive Sentiment: Other broker support remains bullish: Wedbush (outperform, $30 PT), Citizens Jmp (market outperform, $31 PT) and HC Wainwright (buy, PT $42) provide higher upside scenarios that likely underlie investor optimism. Benzinga coverage of analyst moves

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.